DETECT INC

DETECT INC specializes in the design, development, and scalable manufacturing of rapid molecular diagnostic platforms for infectious disease detection, with a focus on at-home and point-of-care applications. The company leverages advanced nucleic acid amplification technologies and integrated microfluidic systems to create high-sensitivity, multi-analyte assays capable of simultaneously detecting SARS-CoV-2 and influenza A/B with reduced time-to-result. Their technical expertise spans assay chemistry optimization, instrument miniaturization, and closed-system diagnostics engineering, enabling robust performance in non-laboratory environments. A key differentiator is their end-to-end capability in transitioning research-grade molecular tests into commercially viable, affordable, high-volume diagnostic products, bridging the gap between laboratory innovation and public health deployment. DETECT INC has established a consistent relationship with the Department of Health and Human Services, delivering critical diagnostic solutions under initiatives such as the Rapid Acceleration of Diagnostics (RADX) program. Their work for HHS centers on accelerating the development and scale-up of next-generation molecular tests to support national pandemic response and decentralized testing infrastructure, demonstrating alignment with public health emergency preparedness priorities. The company’s primary industry focus lies in Research and Development in the Physical, Engineering, and Life Sciences (NAICS 541715) and Analytical Laboratory Instrument Manufacturing (NAICS 334516), reflecting a dual emphasis on diagnostic innovation and precision instrument production. DETECT INC occupies a niche at the intersection of molecular diagnostics and consumer-facing medical device manufacturing, serving the growing demand for accessible, lab-quality testing outside clinical settings. As a small business structured as a 2L entity based in Guilford, Connecticut, DETECT INC operates with agility to support federal health security objectives. While currently holding no formal government certifications, their proven track record in rapid diagnostic development positions them as a specialized provider within the federal biodefense and public health diagnostics ecosystem.